Lisa Miller

A recent study presented at the 2017 Genitourinary Cancers Symposium found that use of antibiotics could damper the efficacy of checkpoint inhibitors, potentially due to the relationship between gut microbiota and antibiotics.

Women experiencing symptoms of menopause are less likely to adhere to treatment.

According to phase II trial findings, adding everolimus to fulvestrant significantly improved progression-free survival for postmenopausal patients with metastatic hormone receptor-positive, HER2-negative breast cancer who are resistant to aromatase inhibitor therapy.